-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $234

Benzinga·12/16/2025 15:04:55
语音播报
Wells Fargo analyst Benjamin Burnett maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $217 to $234.